Impact of pulmonary arterial hypertension and its therapy on indices of heart rate variability

Medicinski Glasnik

Volumn 10, Issue 2, 2013, Pages 249-253

  Can, Mehmet Mustafa ^a   Kaymaz, Cihangir ^b   Pochi, Nartilla ^b   Aktimur, Tugba ^b  

^a Bagcilar Research and Education Hospital   (Turkey)

^b KOSUYOLU HEART AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Cardiovascular autonomic modulation; Pulmonary heart disease; Treatment

Indexed keywords

BOSENTAN; DIURETIC AGENT; ILOPROST; SILDENAFIL; WARFARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; AMBULATORY ELECTROCARDIOGRAPHY; DRUG EFFECTS; HEART RATE; HYPERTENSION;

ELECTROCARDIOGRAPHY, AMBULATORY; HEART RATE; HUMANS; HYPERTENSION;

EID: 84880748504     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Perros F, Dorfmüller P, Humbert M. Current insights on the pathogenesis of pulmonary arterial hypertension. Semin Respir Crit Care Med 2005; 26:355-64.
2. Saggar R, Saggar R, Aboulhosn J, Belperio JA, Zisman DA, Lynch JP 3rd. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30:399-410.
3. Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 2008; 8:171-85.
4. Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007; 28:143-67.
5. Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 2009; 157; 4:625-35.
6. Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009; 26:813-25.
7. Frantz RP, Benza RL, Kjellström B, Bourge RC, Barst RJ, Bennett TD, McGoon MD. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27:780-8.
8. Henkens IR, Gan CT, van Wolferen SA, Hew M, Boonstra A, Twisk JW, Kamp O, van der Wall EE, Schalij MJ, Vonk Noordegraaf A, Vliegen HW. ECG monitoring of treatment response in pulmonary arterial hypertension patients. Chest 2008; 134:1250-7.
9. Biederman RW. Cardiovascular magnetic resonance imaging as applied to patients with pulmonary arterial hypertension. Int J Clin Pract Suppl 2009; 162:20-35.
10. Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther 2009; 3:269-87.
11. Takeda Y, Takeda Y, Tomimoto S, Tani T, Narita H, Kimura G. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med 2010; 10:22.
12. Lammers AE, Munnery E, Hislop AA, Haworth SG. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol 2010; 142:159-65.
13. The Criteria Committee for the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Ninth Ed. New York: Little Brown and Company, 1994.
14. Stone PH. ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: clinical significance and analytic techniques. Ann Noninvasive Electrocardiol 2000; 10:263-78.
15. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143:282-92.
16. Garson A., McNAmara D. Sudden death in a pediatric cardiology population, 1958 to 1983:relation to prior arrhythmias. J Am Coll Cardiol 1985; 5(Suppl 6):134-37B.
17. Rich S, Dantzker D, Ayers S. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-223.
18. Lammers AE, Munnery E, Hislop AA, Haworth SG. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol 2010; 142:159-65.
19. McGowan CL, Swiston JS, Notarius CF, Mak S, Morris BL, Picton PE, Granton JT, Floras JS. Discordance between microneurographic and heart-rate spectral indices of sympathetic activity in pulmonary arterial hypertension. Heart 2009; 95:754-8.
20. Wensel R, Jilek C, Dörr M, Francis DP, Stadler H, Lange T, Blumberg F, Opitz C, Pfeifer M, Ewert R. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J 2009; 34:895-901.
21. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34:1219-63.